
Mary-Ann Davies

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1675391/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children. Clinical Infectious Diseases, 2022, 75, 347-355.	5.8	6
2	Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet, The, 2022, 399, 437-446.	13.7	818
3	Virologic nonâ€suppression and early loss to follow up among pregnant and nonâ€pregnant adolescents aged 15–19 years initiating antiretroviral therapy in South Africa: a retrospective cohort study. Journal of the International AIDS Society, 2022, 25, e25870.	3.0	7
4	Growth patterns of infants with in- utero HIV and ARV exposure in Cape Town, South Africa and Lusaka, Zambia. BMC Public Health, 2022, 22, 55.	2.9	4
5	Reduced amplification efficiency of the RNA-dependent-RNA-polymerase target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests. Journal of Virological Methods, 2022, 302, 114471.	2.1	8
6	Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis. Lancet HIV,the, 2022, 9, e150-e159.	4.7	13
7	Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet, The, 2022, 399, 1141-1153.	13.7	51
8	Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis. Journal of the International AIDS Society, 2022, 25, e25871.	3.0	8
9	Assessing the clinical severity of the Omicron variant in the Western Cape Province, South Africa, using the diagnostic PCR proxy marker of RdRp target delay to distinguish between Omicron and Delta infections – a survival analysis. International Journal of Infectious Diseases, 2022, 118, 150-154.	3.3	22
10	Outcomes of laboratoryâ€confirmed <scp>SARSâ€CoV</scp> â€2 infection in the Omicronâ€driven fourth wave compared with previous waves in the Western Cape Province, South Africa. Tropical Medicine and International Health, 2022, 27, 564-573.	2.3	94
11	Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization. Vaccine, 2022, 40, 3516-3527.	3.8	69
12	Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clinical Infectious Diseases, 2021, 73, e2005-e2015.	5.8	405
13	Virologic response of adolescents living with perinatally acquired HIV receiving antiretroviral therapy in the period of early adolescence (10–14 years) in South Africa. Aids, 2021, 35, 971-978.	2.2	0
14	A mechanistic model for long-term immunological outcomes in South African HIV-infected children and adults receiving ART. ELife, 2021, 10, .	6.0	1
15	Improving Methods to Classify Perinatal versus Nonperinatal HIV Acquisition in Young Adolescents 10–14 Years of Age. Pediatric Infectious Disease Journal, 2021, 40, 453-456.	2.0	2
16	Preterm birth and severe morbidity in hospitalized neonates who are HIV exposed and uninfected compared with HIV unexposed. Aids, 2021, 35, 921-931.	2.2	8
17	Detection of a SARS-CoV-2 variant of concern in South Africa. Nature, 2021, 592, 438-443.	27.8	1,381
18	Lower birth weight-for-age and length-for-age z-scores in infants with in-utero HIV and ART exposure: a prospective study in Cape Town, South Africa. BMC Pregnancy and Childbirth, 2021, 21, 354.	2.4	16

2

#	Article	IF	CITATIONS
19	Overview of SARS-CoV-2 infection in adults living with HIV. Lancet HIV,the, 2021, 8, e294-e305.	4.7	129
20	Variations in the characteristics and outcomes of children living with HIV following universal ART in sub-Saharan Africa (2006–17): a retrospective cohort study. Lancet HIV,the, 2021, 8, e353-e362.	4.7	21
21	Higher COVID-19 mortality in low-income communities in the City of Cape Town – a descriptive ecological study. Gates Open Research, 2021, 5, 90.	1.1	14
22	HIV-1 and SARS-CoV-2: Patterns in the evolution of two pandemic pathogens. Cell Host and Microbe, 2021, 29, 1093-1110.	11.0	73
23	Increased infectious-cause hospitalization among infants who are HIV-exposed uninfected compared with HIV-unexposed. Aids, 2021, 35, 2327-2339.	2.2	22
24	Risk factors for COVID-19 hospitalisation and death in people living with diabetes: A virtual cohort study from the Western Cape Province, South Africa. Diabetes Research and Clinical Practice, 2021, 177, 108925.	2.8	12
25	Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study. The Lancet Global Health, 2021, 9, e1216-e1225.	6.3	131
26	Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. Lancet HIV,the, 2021, 8, e554-e567.	4.7	105
27	Global HIV mortality trends among children on antiretroviral treatment corrected for underâ€reported deaths: an updated analysis of the International epidemiology Databases to Evaluate AIDS collaboration. Journal of the International AIDS Society, 2021, 24, e25780.	3.0	5
28	Age-specific mortality rate ratios in adolescents and youth aged 10–24 years living with perinatally versus nonperinatally acquired HIV. Aids, 2021, 35, 625-632.	2.2	5
29	Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries. Lancet HIV,the, 2021, 8, e766-e775.	4.7	38
30	Impact of Universal Antiretroviral Treatment Eligibility on Rapid Treatment Initiation Among Young Adolescents with Human Immunodeficiency Virus in Sub-Saharan Africa. Journal of Infectious Diseases, 2020, 222, 755-764.	4.0	10
31	Earlier Antiretroviral Therapy Initiation and Decreasing Mortality Among HIV-infected Infants Initiating Antiretroviral Therapy Within 3 Months of Age in South Africa, 2006–2017. Pediatric Infectious Disease Journal, 2020, 39, 127-133.	2.0	17
32	Steep Declines in Pediatric AIDS Mortality in South Africa, Despite Poor Progress Toward Pediatric Diagnosis and Treatment Targets. Pediatric Infectious Disease Journal, 2020, 39, 843-848.	2.0	9
33	Longâ€ŧerm virologic responses to antiretroviral therapy among HIVâ€positive patients entering adherence clubs in Khayelitsha, Cape Town, South Africa: a longitudinal analysis. Journal of the International AIDS Society, 2020, 23, e25476.	3.0	20
34	Timeâ€varying age―and CD4â€stratified rates of mortality and WHO stage 3 and stage 4 events in children, adolescents and youth 0 to 24 years living with perinatally acquired HIV, before and after antiretroviral therapy initiation in the paediatric leDEA Global Cohort Consortium. Journal of the International AIDS Society, 2020, 23, e25617.	3.0	8
35	Trends in CD4 and viral load testing 2005 to 2018: multiâ€cohort study of people living with HIV in Southern Africa. Journal of the International AIDS Society, 2020, 23, e25546.	3.0	27
36	Excess mortality associated with mental illness in people living with HIV in Cape Town, South Africa: a cohort study using linked electronic health records. The Lancet Global Health, 2020, 8, e1326-e1334.	6.3	40

#	Article	IF	CITATIONS
37	Raltegravir use and outcomes among children and adolescents living with HIV in the IeDEA global consortium. Journal of the International AIDS Society, 2020, 23, e25580.	3.0	5
38	Mental health, substance use and viral suppression in adolescents receiving ART at a paediatric HIV clinic in South Africa. Journal of the International AIDS Society, 2020, 23, e25644.	3.0	33
39	Virologic response to efavirenz-based first-line antiretroviral therapy in children with previous exposure to antiretrovirals to prevent mother-to-child transmission. PLoS ONE, 2020, 15, e0233693.	2.5	0
40	Weight-for-age distributions among children with HIV on antiretroviral therapy in the International epidemiology Databases to Evaluate AIDS (IeDEA) multiregional consortium. BMC Research Notes, 2020, 13, 249.	1.4	3
41	International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012–2019. BMJ Open, 2020, 10, e035246.	1.9	63
42	Long-term outcomes in perinatally HIV-infected adolescents and young adults on antiretroviral therapy: a review of South African and global literature. African Journal of AIDS Research, 2020, 19, 1-12.	0.9	8
43	A longitudinal analysis of the completeness of maternal HIV testing, including repeat testing in Cape Town, South Africa. Journal of the International AIDS Society, 2020, 23, e25441.	3.0	6
44	Safety and Effectiveness of Isoniazid Preventive Therapy in Pregnant Women Living with Human Immunodeficiency Virus on Antiretroviral Therapy: An Observational Study Using Linked Population Data. Clinical Infectious Diseases, 2020, 71, e351-e358.	5.8	23
45	Characterizing the doubleâ€sided cascade of care for adolescents living with HIV transitioning to adulthood across Southern Africa. Journal of the International AIDS Society, 2020, 23, e25447.	3.0	13
46	The Impact of Delayed Switch to Second-Line Antiretroviral Therapy on Mortality, Depending on Definition of Failure Time and CD4 Count at Failure. American Journal of Epidemiology, 2020, 189, 811-819.	3.4	19
47	COVID-19 and Pediatric Lung Disease: A South African Tertiary Center Experience. Frontiers in Pediatrics, 2020, 8, 614076.	1.9	10
48	Characteristics and outcomes of adolescents living with perinatally acquired HIV within Southern Africa. Aids, 2020, 34, 2275-2284.	2.2	2
49	Stunting and growth velocity of adolescents with perinatally acquired HIV: differential evolution for males and females. A multiregional analysis from the IeDEA global paediatric collaboration. Journal of the International AIDS Society, 2019, 22, e25412.	3.0	21
50	Distribution of advanced HIV disease from three high HIV prevalence settings in Sub-Saharan Africa: a secondary analysis data from three population-based cross-sectional surveys in Eshowe (South) Tj ETQq0 0 0 rgB	T /Øyverloc	k 20 Tf 50 21
51	What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies. Pediatric Infectious Disease Journal, 2019, 38, 400-405.	2.0	4
52	Research priorities to inform "Treat All―policy implementation for people living with <scp>HIV</scp> in subâ€Saharan Africa: a consensus statement from the International epidemiology Databases to Evaluate <scp>AIDS</scp> (Ie <scp>DEA</scp>). Journal of the International AIDS Society, 2019, 22, e25218.	3.0	32
53	Changes in rapid HIV treatment initiation after national "treat all―policy adoption in 6 sub-Saharan African countries: Regression discontinuity analysis. PLoS Medicine, 2019, 16, e1002822.	8.4	53
54	Timing of combination antiretroviral therapy (cART) initiation is not associated with stillbirth among HIV â€infected pregnant women in Malawi. Tropical Medicine and International Health, 2019, 24, 727-735.	2.3	10

#	Article	IF	CITATIONS
55	Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration. Lancet HIV,the, 2019, 6, e105-e115.	4.7	22
56	Updates to the Spectrum/AIM model for estimating key HIV indicators at national and subnational levels. Aids, 2019, 33, S227-S234.	2.2	52
57	Temporal Trends in Co-trimoxazole Use Among Children on Antiretroviral Therapy and the Impact of Co-trimoxazole on Mortality Rates in Children Without Severe Immunodeficiency. Journal of the Pediatric Infectious Diseases Society, 2019, 8, 450-460.	1.3	3
58	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clinical Infectious Diseases, 2018, 66, 893-903.	5.8	105
59	HIV and adolescents. Current Opinion in HIV and AIDS, 2018, 13, 167-169.	3.8	3
60	Time to First-Line ART Failure and Time to Second-Line ART Switch in the IeDEA Pediatric Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 221-230.	2.1	20
61	Retention and mortality on antiretroviral therapy in sub‣aharan Africa: collaborative analyses of HIV treatment programmes. Journal of the International AIDS Society, 2018, 21, e25084.	3.0	91
62	Adolescent transition among young people with perinatal HIV in high-income and low-income settings. Current Opinion in HIV and AIDS, 2018, 13, 236-248.	3.8	26
63	Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 413-416.	2.1	2
64	Impact of "test and treat" recommendations on eligibility for antiretroviral treatment: Cross sectional population survey data from three high HIV prevalence countries. PLoS ONE, 2018, 13, e0207656.	2.5	16
65	Weight gain of HIV-exposed, uninfected children born before and after introduction of the â€~Option B+' programme in Malawi. Aids, 2018, 32, 2201-2208.	2.2	6
66	Using Observational Data to Inform HIV Policy Change for Children and Youth. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, S22-S26.	2.1	7
67	HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling. Journal of Virus Eradication, 2018, 4, 55-58.	0.5	25
68	Traversing the cascade: urgent research priorities for implementing the â€~treat all' strategy for children and adolescents living with HIV in sub-Saharan Africa. Journal of Virus Eradication, 2018, 4, 40-46.	0.5	44
69	The contribution of observational studies in supporting the WHO â€ [~] treat all' recommendation for HIV/AIDS. Journal of Virus Eradication, 2018, 4, 5-8.	0.5	13
70	Lamivudine monotherapy as a holding regimen for HIV-positive children. PLoS ONE, 2018, 13, e0205455.	2.5	4
71	Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation. Journal of the International AIDS Society, 2018, 21, e25200.	3.0	6
72	Neonatal and infant diagnostic HIV-PCR uptake and associations during three sequential policy periods in Cape Town, South Africa: a longitudinal analysis. Journal of the International AIDS Society, 2018, 21, e25212.	3.0	16

#	Article	IF	CITATIONS
73	Mortality and losses to followâ€up among adolescents living with HIV in the Ie DEA global cohort collaboration. Journal of the International AIDS Society, 2018, 21, e25215.	3.0	56
74	Routine data underestimates the incidence of first-line antiretroviral drug discontinuations due to adverse drug reactions: Observational study in two South African cohorts. PLoS ONE, 2018, 13, e0203530.	2.5	3
75	Medication Side Effects and Retention in HIV Treatment: A Regression Discontinuity Study of Tenofovir Implementation in South Africa and Zambia. American Journal of Epidemiology, 2018, 187, 1990-2001.	3.4	8
76	Models of support for disclosure of <scp>HIV</scp> status to <scp>HIV</scp> â€infected children and adolescents in resourceâ€imited settings. Journal of the International AIDS Society, 2018, 21, e25157.	3.0	11
77	Acceptability and performance of a directly assisted oral HIV self-testing intervention in adolescents in rural Mozambique. PLoS ONE, 2018, 13, e0195391.	2.5	52
78	Assessing the risk of dolutegravir for women of childbearing potential. The Lancet Global Health, 2018, 6, e958-e959.	6.3	5
79	Access to antiretroviral therapy in HIV-infected children aged 0–19 years in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Global Cohort Consortium, 2004–2015: A prospective cohort study. PLoS Medicine, 2018, 15, e1002565.	8.4	33
80	The management and outcomes of Staphylococcus aureus bacteraemia at a South African referral hospital: A prospective observational study. International Journal of Infectious Diseases, 2018, 73, 78-84.	3.3	6
81	The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis. PLoS Medicine, 2018, 15, e1002514.	8.4	98
82	Traversing the cascade: urgent research priorities for implementing the 'treat all' strategy for children and adolescents living with HIV in sub-Saharan Africa. Journal of Virus Eradication, 2018, 4, 40-46.	0.5	27
83	HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling. Journal of Virus Eradication, 2018, 4, 55-58.	0.5	12
84	The contribution of observational studies in supporting the WHO 'treat all' recommendation for HIV/AIDS. Journal of Virus Eradication, 2018, 4, 5-8.	0.5	13
85	Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe. International Journal of Epidemiology, 2017, 46, dyw097.	1.9	30
86	Tenofovir stock shortages have limited impact on clinic―and patientâ€Ievel HIV treatment outcomes in public sector clinics in South Africa. Tropical Medicine and International Health, 2017, 22, 241-251.	2.3	10
87	Where do HIVâ€infected adolescents go after transfer? – Tracking transition/transfer of HIVâ€infected adolescents using linkage of cohort data to a health information system platform. Journal of the International AIDS Society, 2017, 20, 21668.	3.0	45
88	Changes in estimated glomerular filtration rate over time in South African HIVâ€1â€infected patients receiving tenofovir: a retrospective cohort study. Journal of the International AIDS Society, 2017, 20, 21317.	3.0	32
89	Twelveâ€year mortality in adults initiating antiretroviral therapy in South Africa. Journal of the International AIDS Society, 2017, 20, 21902.	3.0	50
90	HIV transmission and retention in care among HIVâ€exposed children enrolled in Malawi's prevention of motherâ€ŧo hild transmission programme. Journal of the International AIDS Society, 2017, 20, 21947.	3.0	28

#	Article	IF	CITATIONS
91	The cascade of care to prevent motherâ€ŧoâ€child transmission in Rio de Janeiro, Brazil, 1996–2013: improving but still some way to go. Tropical Medicine and International Health, 2017, 22, 1266-1274.	2.3	3
92	Improving estimates of children living with HIV from the Spectrum AIDS Impact Model. Aids, 2017, 31, S13-S22.	2.2	47
93	Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?. Aids, 2017, 31, 147-157.	2.2	12
94	HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy—Results From the IeDEA Collaboration. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 319-329.	2.1	58
95	HIV-associated malignancies in children. Current Opinion in HIV and AIDS, 2017, 12, 77-83.	3.8	21
96	HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. Journal of the International AIDS Society, 2017, 20, 21327.	3.0	38
97	Transition from paediatric to adult care of adolescents living with HIV in sub‧aharan Africa: challenges, youthâ€friendly models, and outcomes. Journal of the International AIDS Society, 2017, 20, 21528.	3.0	100
98	Living and dying to be counted: What we know about the epidemiology of the global adolescent HIV epidemic. Journal of the International AIDS Society, 2017, 20, 21520.	3.0	108
99	Universal antiretroviral therapy for HIVâ€infected children: a review of the benefits and risks to consider during implementation. Journal of the International AIDS Society, 2017, 20, 21552.	3.0	26
100	Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia. Clinical Infectious Diseases, 2017, 64, 1343-1349.	5.8	43
101	Estimating the impact of antiretroviral treatment on adult mortality trends in South Africa: A mathematical modelling study. PLoS Medicine, 2017, 14, e1002468.	8.4	102
102	First-line antiretroviral drug discontinuations in children. PLoS ONE, 2017, 12, e0169762.	2.5	7
103	Clinician compliance with laboratory monitoring and prescribing guidelines in HIV-1-infected patients receiving tenofovir. South African Medical Journal, 2016, 106, 369.	0.6	4
104	Incidence of AIDS-defining and Other Cancers in HIV-positive Children in South Africa. Pediatric Infectious Disease Journal, 2016, 35, e164-e170.	2.0	38
105	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	5.8	20
106	Association between hepatitis B coâ€infection and elevated liver stiffness among <scp>HIV</scp> â€infected adults in Lusaka, Zambia. Tropical Medicine and International Health, 2016, 21, 1435-1441.	2.3	15
107	Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale. Drug Safety, 2016, 39, 959-976.	3.2	7
108	Prospects for HIV control in South Africa: a model-based analysis. Global Health Action, 2016, 9, 30314.	1.9	45

#	Article	IF	CITATIONS
109	Survival of HIV-1 vertically infected children. Current Opinion in HIV and AIDS, 2016, 11, 455-464.	3.8	47
110	Growth of HIV-Exposed Uninfected Infants in the First 6 Months of Life in South Africa: The IeDEA-SA Collaboration. PLoS ONE, 2016, 11, e0151762.	2.5	21
111	Growth and Mortality Outcomes for Different Antiretroviral Therapy Initiation Criteria in Children aged 1-5 Years. Epidemiology, 2015, 27, 1.	2.7	19
112	A comparison of death recording by health centres and civil registration in South Africans receiving antiretroviral treatment. Journal of the International AIDS Society, 2015, 18, 20628.	3.0	37
113	Reducing CD4 Monitoring in Children on Antiretroviral Therapy With Virologic Suppression. Pediatric Infectious Disease Journal, 2015, 34, 1361-1364.	2.0	12
114	Growth in Virologically Suppressed HIV-Positive Children on Antiretroviral Therapy. Pediatric Infectious Disease Journal, 2015, 34, e254-e259.	2.0	3
115	Outcomes of Infants Starting Antiretroviral Therapy in Southern Africa, 2004–2012. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 593-601.	2.1	24
116	Getting to 90-90-90 in paediatric HIV: What is needed?. Journal of the International AIDS Society, 2015, 18, 20770.	3.0	13
117	Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. Lancet HIV,the, 2015, 2, e271-e278.	4.7	98
118	CD4+ T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. International Journal of Epidemiology, 2015, 44, 251-263.	1.9	10
119	Age-specific and sex-specific weight gain norms to monitor antiretroviral therapy in children in low-income and middle-income countries. Aids, 2015, 29, 101-109.	2.2	8
120	Immunodeficiency in Children Starting Antiretroviral Therapy in Low-, Middle-, and High-Income Countries. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 62-72.	2.1	49
121	Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. Lancet HIV,the, 2015, 2, e438-e444.	4.7	227
122	The future role of CD4 cell count for monitoring antiretroviral therapy. Lancet Infectious Diseases, The, 2015, 15, 241-247.	9.1	115
123	Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 30-38.	1.3	14
124	Research gaps in neonatal HIV-related care. Southern African Journal of HIV Medicine, 2015, 16, 375.	0.9	4
125	Clinical Mentorship of Nurse Initiated Antiretroviral Therapy in Khayelitsha, South Africa: A Quality of Care Assessment. PLoS ONE, 2014, 9, e98389.	2.5	25
126	Provider-Initiated HIV Testing and Counselling for Children. PLoS Medicine, 2014, 11, e1001650.	8.4	19

#	Article	IF	CITATIONS
127	Effect of Baseline Renal Function on Tenofovir-Containing Antiretroviral Therapy Outcomes in Zambia. Clinical Infectious Diseases, 2014, 58, 1473-1480.	5.8	66
128	Cotrimoxazole prophylactic treatment prevents malaria in children in subâ€Saharan Africa: systematic review and metaâ€analysis. Tropical Medicine and International Health, 2014, 19, 1057-1067.	2.3	27
129	Do Increasing Rates of Loss to Follow-up in Antiretroviral Treatment Programs Imply Deteriorating Patient Retention?. American Journal of Epidemiology, 2014, 180, 1208-1212.	3.4	35
130	Is it safe to drop CD4+ monitoring among virologically suppressed patients. Aids, 2014, 28, 2003-2005.	2.2	20
131	Virologic Response in Children Treated With Abacavir-compared With Stavudine-based Antiretroviral Treatment. Pediatric Infectious Disease Journal, 2014, 33, 617-622.	2.0	29
132	Prognosis of Children With HIV-1 Infection Starting Antiretroviral Therapy in Southern Africa. Pediatric Infectious Disease Journal, 2014, 33, 608-616.	2.0	24
133	Viral load versus CD4+ monitoring and 5-year outcomes of antiretroviral therapy in HIV-positive children in Southern Africa. Aids, 2014, 28, 2451-2460.	2.2	12
134	Kaposi's Sarcoma in HIVâ€infected patients in South Africa: Multicohort study in the antiretroviral therapy era. International Journal of Cancer, 2014, 135, 2644-2652.	5.1	48
135	Task Shifting for the Delivery of Pediatric Antiretroviral Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 414-422.	2.1	38
136	When to Start Antiretroviral Therapy in Children Aged 2–5 Years: A Collaborative Causal Modelling Analysis of Cohort Studies from Southern Africa. PLoS Medicine, 2013, 10, e1001555.	8.4	32
137	Outcomes of Antiretroviral Therapy in Children in Asia and Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 208-219.	2.1	81
138	Zidovudine impairs immunological recovery on first-line antiretroviral therapy. Aids, 2013, 27, 2225-2232.	2.2	13
139	Outcomes of antiretroviral treatment programmes in rural Lesotho: health centres and hospitals compared. Journal of the International AIDS Society, 2013, 16, 18616.	3.0	17
140	Temporal Trends in the Characteristics of Children at Antiretroviral Therapy Initiation in Southern Africa: The IeDEA-SA Collaboration. PLoS ONE, 2013, 8, e81037.	2.5	36
141	Retention in Care of HIV-Infected Children from HIV Test to Start of Antiretroviral Therapy: Systematic Review. PLoS ONE, 2013, 8, e56446.	2.5	39
142	Poor Early Virologic Performance and Durability of Abacavir-based First-line Regimens for HIV-infected Children. Pediatric Infectious Disease Journal, 2013, 32, 851-855.	2.0	21
143	Monitoring of Antiretroviral Therapy and Mortality in HIV Programmes in Malawi, South Africa and Zambia: Mathematical Modelling Study. PLoS ONE, 2013, 8, e57611.	2.5	27
144	Variability of Growth in Children Starting Antiretroviral Treatment in Southern Africa. Pediatrics, 2012, 130, e966-e977.	2.1	46

#	Article	IF	CITATIONS
145	The Contribution of Maternal HIV Seroconversion During Late Pregnancy and Breastfeeding to Mother-to-Child Transmission of HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 417-425.	2.1	129
146	The Effect of Early Initiation of Antiretroviral Treatment in Infants on Pediatric AIDS Mortality in South Africa. Pediatric Infectious Disease Journal, 2012, 31, 474-480.	2.0	46
147	The role of targeted viral load testing in diagnosing virological failure in children on antiretroviral therapy with immunological failure. Tropical Medicine and International Health, 2012, 17, 1386-1390.	2.3	9
148	A biregional survey and review of firstâ€line treatment failure and secondâ€line paediatric antiretroviral access and use in Asia and southern Africa. Journal of the International AIDS Society, 2011, 14, 7-7.	3.0	23
149	Virologic Failure and Second-Line Antiretroviral Therapy in Children in South Africa—The IeDEA Southern Africa Collaboration. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 270-278.	2.1	112
150	Accuracy of immunological criteria for identifying virological failure in children on antiretroviral therapy – The IeDEA Southern Africa Collaboration. Tropical Medicine and International Health, 2011, 16, 1367-1371.	2.3	21
151	Low Rates of Hepatotoxicity in HIV-infected Children on Anti-retroviral Therapy with and without Isoniazid Prophylaxis. Journal of Tropical Pediatrics, 2010, 56, 159-165.	1.5	13
152	Early Mortality and Loss to Follow-up in HIV-Infected Children Starting Antiretroviral Therapy in Southern Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 524-532.	2.1	88
153	Assessing the Contribution of the Immune Reconstitution Inflammatory Syndrome to Mortality in Developing Country Antiretroviral Therapy Programs. Clinical Infectious Diseases, 2009, 49, 973-975.	5.8	21
154	Comparison of T-SPOT. <i>TB</i> Assay and Tuberculin Skin Test for the Evaluation of Young Children at High Risk for Tuberculosis in a Community Setting. Pediatrics, 2009, 123, 38-43.	2.1	186
155	Paediatric antiretroviral treatment programmes in sub-Saharan Africa: a review of published clinical studies. African Journal of AIDS Research, 2009, 8, 329-338.	0.9	18
156	Detection of tuberculosis in HIV-infected children using an enzyme-linked immunospot assay. Aids, 2009, 23, 961-969.	2.2	35
157	Monitoring the South African National Antiretroviral Treatment Programme, 2003-2007: the IeDEA Southern Africa collaboration. South African Medical Journal, 2009, 99, 653-60.	0.6	44
158	Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. South African Medical Journal, 2009, 99, 730-7.	0.6	93
159	Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study. BMC Pediatrics, 2008, 8, 34.	1.7	82
160	Bacillus Calmette–Guérin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy. International Journal of Infectious Diseases, 2008, 12, e99-e105.	3.3	43
161	Antiretroviral treatment for children. South African Medical Journal, 2006, 96, 988-93.	0.6	44
162	Initial experience of a public sector antiretroviral treatment programme for HIV-infected children and their infected parents. South African Medical Journal, 2004, 94, 643-6.	0.6	40